The U.S. Food and Drug Administration (FDA) on Tuesday approved the supplemental Biologics License Application (sBLA) for Merz North America’s Xeomin (incobotulinumtoxinA) for the treatment of chronic sialorrhea, or excessive drooling, in adult patients. Xeomin is the first and only neurotoxin with this approved indication in the U.S. “Until now, there has not been an FDA approved treatment…